IRS Form 8820 Guide: How to Claim the Orphan Drug Credit

1. Introduction – What is Form 8820?

IRS Form 8820, titled Orphan Drug Credit, is an official corporate and business tax schedule issued by the Internal Revenue Service (IRS). It is governed under Section 45C of the Internal Revenue Code (IRC § 45C) in coordination with Section 526 of the Federal Food, Drug, and Cosmetic Act.

This form is used by biotechnology companies, pharmaceutical manufacturers, and clinical research sponsors to calculate and claim a specialized tax credit for the clinical testing of drugs intended to treat rare diseases or medical conditions. As part of the General Business Credit, Form 8820 provides a direct, dollar-for-dollar tax credit equal to 25% of qualified clinical testing expenses.

2. Purpose of the Form – Why Does Form 8820 Exist?

Developing treatments for rare diseases (known as “orphan diseases”) is financially risky because the target patient population is small, making it difficult for drug developers to recover their research and development costs. To incentivize medical innovation in underserved disease areas, Congress enacted the Orphan Drug Act.

Form 8820 fulfills several vital financial and scientific purposes:

• Direct Tax Relief: It offsets corporate income tax liability by providing a 25% federal tax credit on human clinical trial costs.
• Incentivizes Rare Disease Cures: It subsidizes the high cost of testing therapies for diseases affecting fewer than 200,000 individuals in the United States (such as cystic fibrosis, Huntington’s disease, or rare childhood cancers).
• Supplements R&D Incentives: While standard laboratory research is eligible for the general R&D credit on Form 6765, Form 8820 provides a targeted credit specifically for human clinical trials on designated orphan drugs.
• Coordinates Tax Deductions: It ensures that companies properly reduce their deductible research expenses under Section 280C to prevent unfair double tax deductions.

3. Who Needs to File Form 8820?

You must file Form 8820 if your business paid or incurred Qualified Clinical Testing Expenses (QCTEs) during the tax year for an eligible drug. Qualifying filers include:

• Biotechnology & Pharmaceutical Companies: C corporations, S corporations, partnerships, and LLCs conducting human clinical trials for rare disease therapies.
• Clinical Trial Sponsors: Companies that contract with Clinical Research Organizations (CROs), academic medical centers, or hospitals to conduct Phase I, Phase II, or Phase III human clinical trials.
• FDA-Designated Drug Developers: Taxpayers whose candidate drug received formal Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) under Section 526 of the Federal Food, Drug, and Cosmetic Act.
• Pass-Through Equity Holders: Partners and S corporation shareholders who receive an allocated share of the Orphan Drug Credit on Schedule K-1.

4. Who Is Exempt / Not Required to File?

Form 8820 is strictly reserved for human clinical trials on FDA-designated orphan drugs. You do not file Form 8820 under the following conditions:

• Non-Designated Drug Research: Testing conducted on experimental drugs that have not received official orphan status designation from the FDA.
• Pre-Clinical Research: Early-stage laboratory research, molecular synthesis, and animal testing do not qualify for Form 8820 (though they may qualify for the R&D credit on Form 6765).
• Post-Approval Testing: Clinical trials conducted after the FDA has officially approved the drug for commercial sale.
• Funded Clinical Testing: Research funded by government grants, non-profit foundation awards, or commercial contracts where the company bears no financial risk.
• Non-Healthcare Businesses & Individuals: General businesses and retail individual taxpayers never file Form 8820.

5. When to File – Deadlines and Frequency

Form 8820 is an annual tax attachment submitted directly with your business or corporate federal income tax return for the tax year in which the clinical testing expenses were paid or incurred:

• C Corporations (Form 1120): Due annually on April 15, or October 15 with a valid six-month extension.
• Partnerships & S Corporations (Forms 1065 & 1120-S): Due on March 15, or September 15 with an extension.
• The Critical FDA Timing Window: Clinical testing expenses qualify for Form 8820 only if incurred on or after the date the FDA grants orphan drug designation and before the date the FDA grants marketing approval.

6. Where and How to File Form 8820

Form 8820 cannot be submitted as an independent document. It must accompany your primary business income tax return:

• Electronic Filing (E-File): Most corporate tax preparation software programs automatically generate and attach Form 8820 when clinical research expenses are entered, transferring the final credit amount to Form 3800 (General Business Credit), Part III, Line 1h.
• Paper Filing: If filing a physical return, attach Form 8820 directly behind Form 3800 and mail the complete packet to the IRS address as per instructions for your main business return.

7. Step-by-Step Instructions to Fill Form 8820

Form 8820 is a concise one-page tax schedule that calculates the allowable credit from direct clinical trial expenses and pass-through allocations.

Line Item	Item Name	Instructions & Calculation Rules
Line 1	Qualified Clinical Testing Expenses	Enter total qualifying clinical human testing expenses paid or incurred during the tax year for FDA-designated orphan drugs.
Line 2	Current Year Credit Calculation	Multiply Line 1 by 25% (0.25) to calculate the current-year orphan drug credit.
Line 3	Pass-Through Credits	Enter the total orphan drug credit passed through from partnerships, S corporations, estates, or trusts (reported on Schedule K-1).
Line 4	Total Gross Credit	Add Line 2 and Line 3 to determine your total allowable credit before fiduciary allocations.
Line 5	Credit Transferred to Form 3800	Estates and trusts allocate amounts between the trust and beneficiaries. Corporations and individual sponsors enter the full amount from Line 4 and transfer it to Form 3800, Part III, Line 1h.

What Qualifies as a Clinical Testing Expense (QCTE)?

Under Section 45C, qualified clinical testing expenses include three major cost categories incurred during human clinical trials in the United States:

• In-House Clinical Wages: Taxable W-2 wages paid to research scientists, clinical trial coordinators, and medical monitors directly conducting or supervising clinical testing.
• Clinical Supplies: Tangible, non-depreciable materials, medical testing kits, active pharmaceutical ingredients (APIs), and laboratory consumables used up during clinical trials.
• Contract Research Expenses: Payments made to third-party Clinical Research Organizations (CROs), independent clinical trial sites, and medical investigators (subject to statutory contract research rules).

8. Required Documents and Information Needed Before Filling

To substantiate your Orphan Drug Credit and withstand IRS examination, compile the following scientific, legal, and financial records:

• FDA Orphan Drug Designation Letter: The official confirmation letter from the FDA Office of Orphan Products Development confirming the designation date and disease indication under Section 526.
• FDA Investigational New Drug (IND) Documentation: Clinical protocol filings, trial phase notices, and FDA correspondence establishing active human clinical testing.
• Clinical Trial Contracts & CRO Invoices: Itemized statements from contract research organizations and clinical trial sites detailing patient testing dates and services.
• Payroll Registers & Wage Allocations: W-2 wage records and project time-tracking logs for internal clinical research personnel.
• Supply Purchase Invoices: Vendor receipts and material logs for testing supplies consumed during the clinical trials.

9. Common Mistakes to Avoid

Due to overlapping FDA and IRS regulations, biotechnology companies frequently make costly filing errors on Form 8820:

• Claiming Expenses Before FDA Designation: Expenses incurred before the official FDA orphan drug designation letter date do not qualify for Form 8820 (though they may be claimed under the R&D credit on Form 6765).
• Claiming Pre-Clinical Laboratory Research: Form 8820 is strictly for human clinical testing. Animal testing, discovery chemistry, and in vitro screening are excluded.
• Double-Dipping with the R&D Credit: Claiming the exact same research expenses on both Form 8820 (Orphan Drug Credit) and Form 6765 (R&D Credit) is illegal double-counting.
• Failing to Adjust Deductions Under Section 280C: Companies must reduce their deductible clinical research expenses on Form 1120 by the full dollar amount of the Orphan Drug Credit claimed.
• Including Foreign Clinical Testing: Clinical testing conducted outside the United States generally does not qualify, unless the foreign patient population is required due to an insufficient number of U.S. patients.

10. Penalties for Non-Filing or Errors

Because Form 8820 claims an elective general business credit, failing to file simply means forfeiting the tax credit. However, making improper, overstated, or unsubstantiated claims carries severe IRS penalties:

• Total Credit Disallowance: The IRS will revoke the credit upon audit, generating immediate back taxes on disallowed trial expenses.
• Accuracy-Related Penalty (IRC § 6662): A 20% penalty assessed on any tax underpayment resulting from negligence, improper clinical expense categorization, or substantial understatement of tax.
• Statutory Daily Interest: Compounding interest charged on all unpaid corporate tax balances from the original return due date until fully repaid.

11. Related Forms and Schedules

Form 8820 operates as part of the broader federal research and general business credit network:

• Form 3800: General Business Credit (where the Orphan Drug Credit from Line 5 is reported and applied against regular corporate tax).
• Form 6765: Credit for Increasing Research Activities (the general R&D tax credit form used for non-orphan research and pre-clinical discovery).
• Form 1120 / Form 1120-S / Form 1065: Primary corporate and partnership income tax returns.
• Schedule K-1: Partner’s or Shareholder’s Share of Income, Deductions, Credits, etc.

12. Frequently Asked Questions (FAQs)

1. What is the current tax credit rate for Form 8820?

The Orphan Drug Credit rate is 25% of qualified clinical testing expenses paid or incurred during the tax year.

2. What is the difference between Form 8820 and Form 6765?

Form 8820 provides a 25% credit specifically for human clinical testing of FDA-designated orphan drugs. Form 6765 (R&D Credit) provides a credit (typically 14% to 20%) for broader technological research, including pre-clinical discovery and non-orphan commercial products.

3. Can an expense qualify for both Form 8820 and Form 6765?

No. Under federal tax law, you cannot double-dip. You must choose whether to claim an eligible clinical testing expense on Form 8820 (which offers a higher 25% rate) or on Form 6765.

4. Can a pre-revenue biotechnology startup claim Form 8820?

Yes. Even if a biotech company has zero revenue or taxable income, it can file Form 8820 to generate general business credit carryforwards (carried back 1 year and forward up to 20 years) to offset future corporate taxes.

5. Do foreign clinical trial expenses qualify for Form 8820?

Generally, no. Clinical testing must be conducted inside the United States, unless there is an insufficient patient population in the U.S. and the testing is conducted outside the country by a U.S. person or foreign entity under direct U.S. testing authorization.

6. What defines an “Orphan Drug” for tax purposes?

An orphan drug is a biological product or medication officially designated by the FDA under Section 526 of the FD&C Act to treat a rare disease or condition affecting fewer than 200,000 people in the United States.

13. Conclusion – Key Takeaways Summarized

IRS Form 8820 is an indispensable tax incentive for biotechnology and pharmaceutical innovators developing lifesaving treatments for rare diseases. By providing a direct 25% federal tax credit on human clinical trial costs, it significantly reduces the capital expense required to bring orphan therapies through FDA approval.

To ensure full compliance and protect your credits during an audit, confirm official FDA orphan drug designation dates, maintain detailed clinical trial contracts and W-2 wage records, avoid double-counting expenses with the R&D credit, and report your credit accurately on Form 8820 and Form 3800.